Skip to main content
JIANGXI TIANXIN PHARMACEUTICAL CO., LTD. logo

JIANGXI TIANXIN PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 603235 ISIN · CNE100005Q89 LEI · 836800PGVLN9PC718651 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2026-05-13 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603235

About JIANGXI TIANXIN PHARMACEUTICAL CO., LTD.

http://www.jxtxpharm.com/

JIANGXI TIANXIN PHARMACEUTICAL CO., LTD. specializes in the research, development, production, and global distribution of vitamins and fine chemicals. The company is a leading manufacturer of Vitamin B1 (thiamine hydrochloride and thiamine mononitrate) and Vitamin B6. Its extensive product portfolio also includes Biotin, Folic Acid, Vitamin D3, and Ascorbyl Palmitate. These products serve as essential ingredients across the pharmaceutical, food processing, and animal nutrition sectors. The company maintains a competitive edge through integrated production processes and large-scale manufacturing capabilities. It adheres to rigorous quality management standards, holding certifications such as GMP, ISO, and FAMI-QS to ensure product safety and efficacy for its international clientele.

Recent filings

Filing Released Lang Actions
2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and contains the agenda, proposals, board work report, auditor reappointment, profit distribution plan, governance amendments, and other materials prepared for the 2025 Annual General Meeting. It is a packet of meeting materials for the AGM rather than an earnings release, proxy statement, or post‐meeting vote results. Accordingly, it fits the AGM Information category.
2026-05-13 Chinese
关于参加江西辖区上市公司2026年投资者网上集体接待日活动的公告
Regulatory Filings
2026-05-06 Chinese
第三届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Jiangxi Tianxin Pharmaceutical Co., Ltd. It includes approvals of various reports and proposals such as the 2025 annual board work report, general manager work report, audit committee report, profit distribution plan, 2025 annual report and summary, internal control evaluation report, remuneration schemes, audit firm reappointment, fundraising usage reports, ESG report, and others. The document repeatedly states that the detailed contents of these reports are published separately on the Shanghai Stock Exchange website and other designated media. The document itself does not contain the full annual report or financial statements but is a formal announcement of board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document is about board meeting resolutions rather than the full annual report or other reports themselves. The length (4913 characters) is consistent with a detailed board meeting resolution announcement. Therefore, the correct classification is MANG with high confidence.
2026-04-23 Chinese
2025年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as the "2025年度审计报告" (2025 Annual Audit Report) for 江西天新药业股份有限公司. It contains an auditor's opinion, detailed financial statements including consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements. The text includes the auditor's responsibilities, management's responsibilities, and key audit matters, which are typical components of a formal audit report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is a standalone Audit Report, not a full Annual Report (10-K) or other filing types. Hence, the correct classification is Audit Report / Information (AR).
2026-04-23 Chinese
关于2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and actual use of funds raised by Jiangxi Tianxin Pharmaceutical Co., Ltd. for the fiscal year 2025. It includes comprehensive financial tables, descriptions of fund management policies, project investment details, changes in investment projects, and auditor and sponsor opinions. The document references regulatory approvals, specific dates, and detailed financial data related to the use of raised funds. It is not a brief announcement or a certification letter but a substantive report on fundraising capital usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (13,274 characters) and content confirm it is a full report rather than a mere announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2026-04-23 Chinese
2025年度独立董事述职报告-刘桢
Regulatory Filings Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from Jiangxi Tianxin Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, oversight of financial reports, communication with auditors, and governance activities during the year. The content focuses on the independent director's performance and compliance with laws and company regulations, rather than presenting financial statements or audit results themselves. The document length is 3763 characters, which is relatively short and reads like a formal report or statement by the independent director rather than a full annual report or audit report. It is not a certification letter or a brief announcement. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance-related report by an independent director about their duties and observations, not a full financial or audit report, nor a meeting material or voting result.
2026-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.